Tisotumab Vedotin Shows Similar Responses in Radiated and Non-Radiated Cervical Cancer Lesions
A retrospective review found tisotumab vedotin produced similar response rates in radiated and non-radiated cervical cancer lesions. In the 29-patient cohort, median overall survival was 11.0 months and median progression-free survival was 2.8 months.
Tisotumab vedotin-tftv produced similar responses in radiated and non-radiated fields among patients with recurrent cervical cancer in a retrospective, single-institution review shared in a poster at the 2026 SGO Annual Meeting on Women’s Cancer. Among 14 patients with evaluable lesions in both radiated and non-radiated fields at treatment initiation, the objective response rate was 42.9% in radiated fields vs 35.7% in non-radiated fields, and the clinical benefit rate was 64.3% vs 71.4%, respectively.
Among those 14 patients, the best response achieved was partial response in 42.9%, stable disease in 21.4%, and progressive disease in 35.7% among radiated fields, compared with complete responses in 7.1%, partial responses in 28.6%, stable disease in 35.7%, and progressive disease in 28.6% among non-radiated fields (P = .7092). The objective response rate was 42.9% in radiated fields vs 35.7% in non-radiated fields (P >.9999), and the clinical benefit rate was 64.3% vs 71.4%, respectively (P >.9999).
Among all evaluable lesions in radiated or non-radiated fields at the time of tisotumab vedotin initiation, the best response achieved in 19 lesions in radiated fields was a partial response in 47.4%, stable disease in 15.8%, and progressive disease in 36.8%, compared with a complete response in 5.9%, partial response in 29.4%, stable disease in 29.4%, and progressive disease in 35.3% among 17 lesions in non-radiated fields (P = .4910). The objective response rate was 47.4% in radiated fields vs 35.3% in non-radiated fields (P = .5160), and the clinical benefit rate was 63.2% vs 64.7%, respectively (P >.9999).
In the overall cohort of 29 patients who received tisotumab vedotin, the best response was complete response in 0%, partial response in 34.5%, stable disease in 17.2%, and progressive disease in 48.3%. The objective response rate was 34.5%, and the clinical benefit rate was 51.7%. Median overall survival was 11.0 months, and median progression-free survival was 2.8 months.
Treatment outcomes included dose reduction and dose delay in 48.3% each, with treatment being discontinued due to progression in 72.4%, patient preference in 6.9%, hospice/death in 10.3%, and ongoing reasons in 10.3%. The review included patients with recurrent cervical cancer who received treatment with tisotumab vedotin from October 2021 to July 2025. Initial treatment included chemoradiotherapy in 37.9%, surgery plus chemoradiotherapy in 17.2%, and chemotherapy in 17.2%, and prior treatment was immunotherapy in 93.1%, bevacizumab in 79.3%, and radiation in 75.9%.
Disease histology was most commonly squamous cell in 58.6%, followed by adenocarcinoma in 34.5% and other types in 6.9%. Initial disease stage was most commonly IV in 48.3% and III in 37.9%. The review stated that lesions within previously radiated fields demonstrated comparable clinical responses to lesions in non-radiated fields.